Mironova Labs
Q1 2026 Kickoff
March · Fairfield, NJ
Building the Foundation for Scale
Context
What this meeting is about
A chance to get everyone on the same page — where we're headed, what's in the pipeline, and how we're organizing around it.
We've got a lot of volume coming in Q2 and we'll need to run multiple campaigns at once. That takes coordination.
We're growing the team and adding new product lines — good problems to have, but they need structure.
This is about alignment: shared priorities, clear roles, and fewer surprises.
Vision
Where we're going
Parallel production
Move from running one program at a time to multiple concurrent campaigns — without compromising purity, timelines, or documentation.
Multi-platform company
PGs remain our core. DMTMM and metal-organic precursors are shipping product lines. EGT + formulations expand our reach. Strem partnership brings new molecules to evaluate.
Systems-driven org
One connected data model from raw material to customer shipment. Compliance as a byproduct of doing the work — not extra overhead.
Q1 Theme
Parallel Execution
The ability to run multiple programs at once — reliably
Today
one run, then the next
Q2 and beyond
concurrent production, R&D, QC
Priorities
What we're focused on
Team
Who owns what
Leadership + Operations
COO
Production mgmt, operational leadership
Facility Manager + Operator
Facility, safety, equipment, inventory
Production Operator
Batch execution, reactor operations
Facility Operations
Maintenance, cleaning, facility upkeep
All teams report to Ted
R&D + Quality
Director of R&D
R&D strategy, process dev, scale-up
Senior Chemist
Process development
Analytical Chemist
QC testing, method validation, instruments
Operator + Chemist
EGT process refinement & production
Operator + Chemist
Production + R&D initiatives
Glen + Brandon dual-report to Ted for production
Business & Admin
Senior Sales Specialist
Sales strategy, client relationships, revenue growth
Business Administrator
Procurement, billing, HR, QA docs
Business Admin (Part-time)
Administrative support
Arju reports to Liam
Technology
CTO
Helix, systems, AI adoption, digital workflows
Athena — 2026
Production pipeline
Six confirmed orders. Dates are commitments, not estimates.
Order 12
275g · TAFEA
Order 6
265g · CEA
Order 8
400g · CEA
Order 9
267g · CEA
Order 10
700g · CEA
Order 11
425g · CEA
Pipeline + Risk
What's coming — and what it means
Additional PGS Demand (Q2)
All tentative — pending customer confirmation
What this means for us
April–May crunch
Orders 12, 6, 8 land within 25 days. Add CLO-1PE and BIM-1PE and that's 5 campaigns in 6 weeks.
2kg+ CEA committed
Each batch needs reactor time, QC, docs. Starting materials and solvents must be ordered now.
Everyone is in the critical path
R&D → Cliff → Cristina → Arju. A delay at any step cascades to delivery.
This is not a planning exercise — it's already happening
Research & Development
Four R&D pillars
Each pillar has a distinct strategic role. Together they build a multi-platform company.
Ergothioneine
Our highest-upside molecule. Multi-market platform across cosmetic, nutritional, and pharma.
Constraint: cost + scalable supply
Prostaglandins
Core revenue. Focus on yield improvement, purity consistency, and reducing batch-to-batch variability.
Active: 6 Athena orders in pipeline
Specialty Chemicals
DMTMM and metal-organic precursors are established product lines, now selling. Strem Chemicals distributes — and brings us new molecules to evaluate for manufacturing.
Shipping now via Strem
Formulations
EGT + Vit C synergy is established IP. Expanding into retinol stabilization, encapsulation, and delivery systems.
EGT + Vit C: proven, shipping
EGT Deep Dive
Ergothioneine — three markets
Enter through cosmetics for margin. Expand to nutritional for volume. Build toward pharma for defensibility.
Cosmetic
Nutritional
Pharmaceutical
Core Business
Prostaglandins + process
Active Portfolio
TAFEA
Tafluprost EA
CLOEA
Cloprostenol EA
CLO-IPE
Cloprostenol IPE
BIM
Bimatoprost
35+ years of synthesis expertise. Reliable recurring demand from cosmetic and pharma clients. This is the engine that funds everything else.
Active Process Development
Recrystallization
Refining solvent systems and cooling profiles for higher recovery.
Purification
Crystallization-first strategies to reduce chromatography dependence.
Yield Optimization
Reaction parameter tuning across key PG intermediates to improve gram-per-batch output.
Goal: better yield, higher purity, lower cost per gram
Opportunities
What's next in R&D
Retinol Stabilizer
EGT as a protective co-ingredient. Solves the #1 anti-aging formulation challenge.
Encapsulation
Improved stability, controlled release, and enhanced skin penetration.
Microbiome
Emerging research on EGT's role in skin microbiome health and modulation.
Fermentation Supply
Partnership-based production to unlock cost-competitive EGT at volume.
Open floor
Let's talk about what matters most right now.
What feels unclear or undercooked?
Where are we most likely to get stuck in Q2?
What should we stop doing — or start doing differently?
Is anything missing from this plan?
Mironova Labs · Q1 2026 · Confidential